Sign in

    Kyuwon (Paul) Choi

    Research Analyst at Goldman Sachs

    Kyuwon (Paul) Choi is an Equity Analyst and SMid Cap Biotechnology Specialist at Goldman Sachs, providing research coverage for key biotech and pharmaceutical companies such as Amarin PLC, Silverback Therapeutics, Vir Biotechnology, and Magenta Therapeutics. Renowned for his performance, Choi has issued 398 price targets across 40 stocks, achieving a 60% target met ratio and an average upside of 31% within about five months, with highly ranked calls like an 8.59% gain on Vir Biotechnology completed in one day. He joined Goldman Sachs in December 2017, bringing prior equity research experience from Barclays, SunTrust Robinson Humphrey, ICR, Merrill Lynch, and Caris & Co., and holds advanced degrees from the University of Chicago and Northwestern University. Paul K. Choi is officially registered with FINRA and licensed as a securities professional at Goldman Sachs & Co. LLC.

    Kyuwon (Paul) Choi's questions to Vir Biotechnology (VIR) leadership

    Kyuwon (Paul) Choi's questions to Vir Biotechnology (VIR) leadership • Q1 2025

    Question

    Kyuwon (Paul) Choi inquired about the rationale behind the new triplet combination strategy involving a Virion asset, which is the subject of an EASL late-breaker. He also asked for an update on the enrollment timelines for the ECLIPSE-1 and ECLIPSE-2 studies.

    Answer

    Mark Eisner (Executive) clarified that the triplet study is conducted by Virion, not VIR, although VIR provided the assets for the trial. For VIR's own trials, he stated that the company aims to complete enrollment for ECLIPSE-1 by the end of 2024 to meet an estimated study completion date of late 2026. He also noted that ECLIPSE-2 has a shorter 24-week primary endpoint, and further guidance on its timing will be provided later.

    Ask Fintool Equity Research AI

    Kyuwon (Paul) Choi's questions to UroGen Pharma (URGN) leadership

    Kyuwon (Paul) Choi's questions to UroGen Pharma (URGN) leadership • Q4 2024

    Question

    Kyuwon (Paul) Choi of Goldman Sachs asked if the company has stress-tested higher pricing for UGN-102 given its impressive durability data and how UroGen plans to position UGN-103 versus UGN-102, including a potential switch strategy.

    Answer

    President and CEO Liz Barrett confirmed that UroGen is re-evaluating UGN-102 pricing upwards due to the strong durability data, with research currently underway. Regarding the product transition, she explained the strategy is to eventually take UGN-102 off the market after UGN-103 is established, shifting the entire business to the new product to leverage its longer patent protection and create a barrier for potential generics.

    Ask Fintool Equity Research AI